New cancer drug ZN-c3 shows early promise in solid tumor trial

NCT ID NCT04158336

Completed Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the drug is worth testing in larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Azenosertib (also called ZN-c3)
What this could lead to: If this drug works, it could point toward a new treatment option for people with solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not proof of effectiveness. Many cancer drugs that look promising in early testing fail in later, larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Site 0100

San Antonio, Texas, 78229, United States
Site 0101

Detroit, Michigan, 48201, United States
Site 0102

Tucson, Arizona, 85719, United States
Site 0103

Houston, Texas, 77030, United States
Site 0167

Newport Beach, California, 92663, United States
Site 0171

Chicago, Illinois, 60637, United States
Site 0173

New York, New York, 10029, United States
Site 0179

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.